期刊文献+

硼替佐米对淋巴瘤细胞株体外药物敏感性及临床意义的研究

Sensitivity experiment of Bortezomib for lymphoma cell lines in vitro and its clinical significance
原文传递
导出
摘要 目的研究以7种人非霍奇金淋巴瘤(NHL)细胞株为实验对象,以细胞抑制率、半数抑制浓度(IC50)为指标,研究硼替佐米(Bortezomib,BZM)对7种淋巴瘤细胞株的体外敏感状况,从而为临床用药提供实验理论依据。方法 MTT法检测细胞抑制率,并计算半数抑制浓度IC50值。结果 7种淋巴瘤细胞株均对BZM敏感,但BZM对不同淋巴瘤细胞株的敏感性存在差异。结论 BZM对B细胞型、T细胞型淋巴瘤细胞株均敏感。 Objective To investigate the sensitivity of seven human non-Hodgkin's lymphoma cell lines to bortezomib using in vitro MTT assay and provide theoretical basis for clinic.Methods The sensitivity of seven lymphoma cell lines to bortezomib was tested using in vitro MTT assay,and calculating the IC50.Results All the seven lymphoma cell lines were sensitive to bortezomib.The sensitivity of different cells to bortezomib varied.Conclusions Non-Hodgkin's lymphoma involving B-cell type and T-cell type both sensitive to bortezomib.
出处 《医药论坛杂志》 2012年第4期22-24,共3页 Journal of Medical Forum
关键词 BZM 非霍奇淋巴瘤细胞株 MTT Bortezomib Non-Hodgkin's lymphoma cell line MTT
  • 相关文献

参考文献10

  • 1Fribley A, Wang CY. Proteasame inhibitor induces apoptosis through induction of endoplasmic reticulum stress [ J ]. Cancer Biol Ther,2006,5 (7) :745-748.
  • 2Cheriyath V, Jacobs BS, Hussein MA. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors [ J]. Drugs R D, 2007,8( 1 ) :1-12.
  • 3OConnor OA, WrightJ, MoskowitzC, et al. Phase II clinical expe- rience with the novel proteasome inhibitor bortezomib in patients with indolent non - Hodgkin's lymphoma and mantle cell lym- phoma[ J]. J Clin Onco1,2005,23 (4) :676-684.
  • 4Richardon PG, Barlogie B, Berenson J, et al. Extended follow - up of a phase lI trial in relapsed, refractory multiple myeloma [ J]. Cancer,2006,106 (6) : 1316-1319.
  • 5Fisher RI,Berustein SH, Kah BS, et al. Multieenter phaseII study of bortezomib in patients with relapsed or refractory mantle cell lymphoma [ J ]. J Clin Onco1,2006,24 ( 30 ) :4867-4874.
  • 6Belch A, Kouroukis CT, Crum PM, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Insti- tute of Canada Clinical Trials Group trial IND150[ J]. Ann On- col ,2007,18( 1 ) : 116-121.
  • 7Zelenetz AD, Mac - Gregor Cortelli B, Sarasohn D, et al. Time to treatment response in patients with follicular lymphoma treated with hortezomib is longer compared with other histologic sub- types [ J ]. Clinical cancer research,2010,16 (2) :719-726.
  • 8Zinzani PL, Musuraca G, Tani M, et al. Phase II of proteasome inhibitor bortezomib in patients with relapsed or refractory cuta- neous T - cell lymphoma [ J ]. J Clin Oncol, 2007,25 ( 27 ) : 4293-4297.
  • 9Farid M, Yau YQW,Tay K, et al. A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma[J]. Acta Oneologica,2011,50(4) : 589-590.
  • 10Shen L,Au WY,Wong KY,et al. Cell death by bortezomib in- duced mitotic catastrophe in natural killer lymphonm cells [ J ]. Mol Cancer Ther,2008,7 ( 12 ) :3807-3815.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部